Preferred Label : Flumatinib Mesylate;
NCIt synonyms : 4-(4-Methyl-piperazin-1-ylmethyl)-N-[6-methyl-5-(4-pyridin-3-yl-pyrimidin-2-ylamino)-pyridin-3-yl]-3-trifluoromethyl-benzamide
Mesylate;
NCIt definition : The orally bioavailable, mesylate salt form of the tyrosine kinase inhibitor flumatinib,
with potential antineoplastic activity. Upon administration, flumatinib inhibits the
wild-type forms of Bcr-Abl, platelet-derived growth factor receptor (PDGFR) and mast/stem
cell growth factor receptor (SCFR; c-Kit) and forms of these proteins with certain
point mutations. This results in the inhibition of both Bcr-Abl-, PDGFR- and c-Kit-mediated
signal transduction pathways, and the proliferation of tumor cells in which these
kinases are overexpressed. Bcr-Abl fusion protein is an abnormal, constitutively active
enzyme expressed in Philadelphia chromosome positive chronic myeloid leukemia (CML),
acute lymphoblastic leukemia (ALL) or acute myelogenous leukemia (AML). PDGFR, upregulated
in many tumor cell types, is a receptor tyrosine kinase essential to cell migration
and the development of the microvasculature. c-kit, a receptor tyrosine kinase mutated
and constitutively activated in certain tumors, plays a key role in tumor cell survival,
proliferation, and differentiation.;
UNII : 95Y8L63NBC;
InChIKey : ZSASDYCFROUKTJ-UHFFFAOYSA-N;
CAS number : 895519-91-2; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 895519-91-2
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : HH-GV-678 Mesylate;
Origin ID : C117723;
UMLS CUI : C3896942;
- Semantic type(s)
- concept_is_in_subset
- has_free_acid_or_base_form
- is_salt_form_of